文献速递生殖医学

口服维生素D补充对IVF女性颗粒细胞基因表达的影响

Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF.
PubMed 文献 · Hum Reprod · 2021-01-01

结果显示补充组卵泡液25-羟基维生素D浓度显著升高,但其他激素水平无差异;颗粒细胞转录组出现44个差异表达基因,提示维生素D可能参与抗氧化防御。

要点

  • 维生素D补充未改变卵泡液中除25-羟基维生素D外的激素水平。
  • 补充组颗粒细胞VDR、GSTA3、IL21R上调,PTGS2、KLF4等下调。
  • 维生素D可能作为抗氧化防御的调节因子影响卵泡微环境。

核心结论

  • 口服维生素D补充可在黄素化颗粒细胞中诱导转录组特征,但不改变卵泡液激素水平。
  • 维生素D可能作为防止卵巢过度刺激反应的守护因子。

研究设计与样本

  • SUNDRO临床试验的次要结局分析,随机双盲安慰剂对照。
  • 纳入145名维生素D缺乏(<30 ng/ml)的IVF女性,随机接受维生素D或安慰剂。
  • 激素分析队列:维生素D组50例,安慰剂组45例;基因表达队列:维生素D组20例,安慰剂组30例。

主要发现

  • 取卵时卵泡液25-羟基维生素D浓度在维生素D组为39.5 ng/ml,安慰剂组为13.8 ng/ml,差异2.8倍(P < 0.001)。
  • 未检测到其他激素(如醛固酮、雄烯二酮、皮质醇、雌二醇、孕酮、睾酮等)的组间差异。
  • 安慰剂组中25-羟基维生素D与孕酮(r = 0.31, P = 0.03)和雌二醇(r = 0.45, P = 0.002)呈弱相关,维生素D组无此相关。
  • RNA测序鉴定出44个差异表达基因;RT-PCR验证显示维生素D组VDR、GSTA3、IL21R上调,PTGS2、KLF4、TRPC4、VEGF、RXRB、AGER下调。
  • IPA提示维生素D参与抗氧化防御通路。

关键数值与推荐

  • 维生素D缺乏定义为<30 ng/ml。
  • 纳入标准:年龄18-39岁,BMI 18-25 kg/m2,既往IVF周期<3次。
  • 所有抽吸卵泡在hCG触发日直径≥11 mm。

临床怎么用

  • 对于维生素D缺乏的IVF女性,补充维生素D可能通过改变颗粒细胞基因表达影响卵泡微环境,但不直接改变卵泡液激素水平。
  • 临床可考虑监测维生素D水平并补充,但不应期望通过补充迅速改变卵泡液激素环境。

局限性

  • 干预时间(取卵前2-12周)仅能观察对卵泡生长最后阶段的影响。
  • 仅分析优势卵泡的激素谱,颗粒细胞数据反映所有可抽吸卵泡的混合转录组。
  • 使用控制性卵巢刺激后的黄素化颗粒细胞,可能与自然发育卵泡的颗粒细胞功能不同。
  • RNA测序样本量小(每组3例),IPA分析需P-adjusted <0.08而非<0.05。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does oral Vitamin D supplementation alter the hormonal milieu of follicular fluid (FF) and the transcriptomic profile of luteinised granulosa cells (GCs) in women with Vitamin D deficiency undergoing IVF? SUMMARY ANSWER: A transcriptomic signature relevant to oral Vitamin D supplementation in luteinised GCs was demonstrated, although Vitamin D supplementation did not alter hormone levels in FF. WHAT IS KNOWN ALREADY: Vitamin D deficiency is linked to lower live birth rates among women undergoing IVF. It is unclear whether Vitamin D elicits a targeted action in reproductive physiology or is a surrogate marker of overall well-being. Several in-vitro studies, but none in vivo, have examined the impact of Vitamin D on the periovulatory follicle, focusing on GCs as a proxy marker of oocyte competence. STUDY DESIGN, SIZE, DURATION: We present a report of secondary outcomes from the SUNDRO clinical trial, which was launched in 2016 to determine whether Vitamin D supplementation can improve the IVF outcomes of women who are deficient in Vitamin D (<30 ng/ml). FF samples of 145 women who were randomised to receive Vitamin D or placebo from March 2017 to January 2019 were collected. All follicles that were aspirated in our study measured ≥11 mm on the day of hCG trigger. The first cohort of samples was collected from the dominant follicle of each participant and utilised for hormone profiling (n = 50 Vitamin D, n = 45 Placebo). For the second cohort, the follicle aspirates of each participant were pooled to create a single FF sample, which was used for the isolation of GCs for gene expression studies (n = 20 Vitamin D, n = 30 placebo). Six of the samples from the second cohort were used for RNA-sequencing analysis (n = 3 Vitamin D, n = 3 placebo). PARTICIPANTS/MATERIALS, SETTING, METHODS: Two academic infertility units were involved in the recruitment of the participants, who received a single dose of oral 25-hydroxyvitamin D (600 000 IU) or placebo, 2-12 weeks before oocyte retrieval. Women in both groups were deficient in Vitamin D, aged 18-39 years with a normal BMI (18-25 kg/m2) and <3 previous IVF cycles. The FF was aspirated at the time of oocyte retrieval and stored. Liquid chromatography tandem mass spectrometry was used to measure FF abundance of 25-hydroxyvitamin D, aldosterone, androstenedione, cortisol, cortisone, corticosterone, 11-deoxycorticosterone, 11-deoxycortisol, 21-deoxycortisol, dehydroepiandrosterone, dehydroepiandrosterone sulfate, dihydrotestosterone, oestradiol (E2), 17-OH-hydroxyprogesterone, progesterone (P4) and testosterone. GCs were isolated from pooled FFs and the transcriptome was evaluated by RNA-sequencing and RT-PCR. Ingenuity pathway analysis (IPA) was used to assess the top canonical pathways and upstream regulators mediating the action of Vitamin D. MAIN RESULTS AND THE ROLE OF CHANCE: At oocyte retrieval, FF concentration of 25-hydroxyvitamin D was 2.8-fold higher (P < 0.001) in the Vitamin D group (39.5 ng/ml; n = 50) compared to placebo (13.8 ng/ml; n = 45) but no other hormonal differences were detected. In the placebo group, but not the Vitamin D group, weak correlations of 25-hydroxyvitamin D concentration with P4 (r = 0.31, P = 0.03) and E2 (r = 0.45, P = 0.002) were observed. RNA-sequencing identified 44 differentially expressed genes in the GCs of patients who received Vitamin D (n = 3) compared to placebo (n = 3). RT-PCR demonstrated upregulation of VDR (vitamin D receptor), GSTA3 (glutathione S-transferase A3) and IL21R (interleukin 21 receptor), and downregulation of P T GS2 (prostaglandin-endoperoxide synthase 2), KLF4 (kruppel-like factor 4), T RP C4 (transient receptor potential cation channel subfamily C member 4), VEGF (vascular endothelial growth factor), RXRB (retinoid X receptor beta) and AGER (advanced glycosylation end-product specific receptor) genes in the Vitamin D (n = 17) versus placebo (n = 27) group. IPA suggested roles of Vitamin D in antioxidant defence. LIMITATIONS, REASONS FOR CAUTION: Interpretation of the data is influenced by our intervention strategy (2-12 weeks prior to retrieval). As folliculogenesis may last 5-6 months, our protocol can only examine with confidence the impact of Vitamin D on the final stages of follicular growth. Furthermore, we examined the hormonal profile of the dominant follicle only, while the GC data reflect the transcriptome of all (pooled) follicles large enough to be used for IVF. Luteinised GCs from controlled ovarian stimulation were used in this study, which may be functionally distinct from the GCs of developing follicles. Moreover, the sample size for RNA-sequencing analysis was low (n = 3 per group), regardless of validation by RT-PCR that was performed on a larger cohort, introducing complexity to the IPA analysis, which required an input of data with P-adjusted <0.08 instead of <0.05 to be informative. WIDER IMPLICATIONS OF THE FINDINGS: This is the first in-vivo study to show that Vitamin D supplementation alters gene expression in luteinised GCs. In contrast to some in-vitro evidence, no effect of the intervention on expression of genes encoding steroidogenic enzymes was observed. Unlike other studies, our results suggest that supplementation with Vitamin D is unlikely to directly influence hormone availability in FF. Our findings instead reinforce the hypothesis that Vitamin D could be considered one of the gatekeepers in protecting against an exaggerated response to ovarian stimulation. STUDY FUNDING/COMPETING INTEREST(S): The study has been funded by the Italian Ministry of Health (RF-2013-02358757) following peer review in the competitive 'Bando di Ricerca Finalizzata e Giovani Ricercatori 2013' for the clinical trial SUNDRO (EudraCT registration number 2015-004233-27). There are no competing interests. TRIAL REGISTRATION NUMBER: EudraCT registration number 2015-004233-27.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Makieva S, Reschini M, Ferrari S, et al. Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF. Hum Reprod. 2021. PMID: 33305818. doi:10.1093/humrep/deaa262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。